As previously announced (announcement), Omnitech has introduced an innovative patented Partial Endometrial Ablation (PEA) procedure and device that prevents the risks of long term complications associated with Global/total Endometrial Ablation (GEA) procedures.

I am pleased to announce that the debut and exhibit of our (PEA) Device and Procedure at the AAGL 37th Global Congress in Las Vegas (October 28-November 1) was a huge success and interest by Doctors and Industry was beyond our expectations. Included in the exhibit was IRB post hysterectomy human tissue testing results showing the (PEA) device to be substantially equivalent to hysteroscopic roller ball ablation with the following advantages:

• Office based procedure requiring only diagnostic hysteroscopy skill
• Direct vision placement and tissue effect monitoring
• Less than two minute treatment time
• Use of standard office equipment (telescope and generator).

The obvious major advantage over (GEA) devices and procedures is that the (PEA) device and procedure does not cause the long term complications associated with Global / Total Endometrial Ablation.

Eight major medical device companies have expressed extreme interest in securing this opportunity. We are now beginning the process of generating an option offer to be issued to the interested parties.

These options are:
• Acquisition of Omnitech Systems, Inc.
• Strategic Partnership on the (PEA) Project

Omnitech is continuing to move forward on the commercialization of the (PEA) device. As the product design evolves Omnitech will be updating this website.